Oishi Koseido

What Oishi Koseido does

Oishi Koseido Co., Ltd. (株式会社大石膏盛堂) is a privately held Japanese pharmaceutical manufacturer headquartered in Tosu, Saga Prefecture, founded in 1907 and incorporated in 1950. The company specializes in adhesive transdermal patches — gel patches (パップ剤), plasters (プラスター剤), and tapes (テープ剤) — built on formulation know-how accumulated over more than 110 years, with drug delivery system (DDS) capabilities spanning topical analgesic, anti-inflammatory, and bronchodilator therapeutics. It operates a four-building manufacturing complex at the Yamaura Factory (production area of 15,025 m²) producing approximately 300 product items under GMP, GQP, and GVP compliance, with FDA-approved facilities for international export.

The business operates three revenue streams: (1) proprietary-brand OTC and ethical/prescription pharmaceuticals sold through Japanese pharmacies, drugstores, and medical institutions (products under the BS Ban, Pasuman Shippu, Rooki Effect, and Loxi Effect families; ethical products include HAPSTAR ID, Felbinac PAP YUTOKU, Ketoprofen Tape PATELL, and TULOBUTEROL Tape VTRS); (2) OEM/contract manufacturing of patches for over 150 pharmaceutical companies including Kyorin Rimedio, Takata Pharmaceutical, Teikoku Seiyaku, Nichi-Iko, Nippon Chemiphar, Nihon Generic, Pfizer Japan, Mylan (now Viatris), and Yutoku Pharmaceutical; and (3) international export through US partner Scilex Pharmaceuticals of ZTlido (lidocaine topical system) 1.8%, an FDA-approved (February 2018) proprietary patch that delivers equivalent analgesic efficacy to competitor 700mg lidocaine patches using only 36mg of active ingredient. The company also markets Satta, an entry into men's cosmetics launched in November 2021 in collaboration with Saga University.

Revenue is anchored at approximately 10 billion yen (~USD 90 million) per a 2019 disclosure, placing Oishi Koseido in the mid-tier Japanese pharmaceutical manufacturer category. The company is family-influenced and controlled through affiliated entity Oishi Holdings Co., Ltd., with current President & Representative Director Kenichi Ito (appointed September 2021) overseeing a generationally continuous management team. Its 1,000–11,500-cited public-facing employee range notwithstanding, the Yamaura facility alone employs 296 production staff and 50 quality assurance personnel. Headcount is concentrated in Tosu, with additional sales offices in Osaka and Tokyo and a distribution warehouse (Yatsugatake) in Nagano Prefecture.

Name

Oishi Koseido

Legal name

株式会社大石膏盛堂

Website

https://o-koseido.co.jp

Company type

Private

Founded year

1907

Operating status

Operating

Headcount range

11–50 employees

Short description

Oishi Koseido is a privately held Japanese pharmaceutical manufacturer, founded in 1907 and headquartered in Tosu, Saga Prefecture, specializing in adhesive transdermal patches (gel patches, plasters, and tapes) for OTC pain relief, prescription drugs, OEM contract manufacturing for 150+ pharma partners, and FDA-approved export of ZTlido to the United States via Scilex Pharmaceuticals.

Ownership category

akta.pro rank

Product category

Transdermal Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

Keywords

• Transdermal patch manufacturing
• Pharmaceutical OEM services
• Topical pain relief patches
• Prescription adhesive patches
• Generic transdermal drugs

Headquarters

HQ city

Saga

HQ country

Japan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing and Sales (Proprietary Brands): Development, manufacturing, and sale of proprietary OTC and ethical (prescription) adhesive transdermal patch products under own brand names (e.g., Pasuman Shippu, BS Ban, Rooki Effect) through pharmacies, drugstores, and medical institutions in Japan.
2. OEM/Contract Manufacturing: Contract manufacturing of gel patches, plasters, and tapes for over 150 pharmaceutical company clients including Kyorin Rimedio, Takata Pharmaceutical, Teikoku Seiyaku, Nichi-Iko, Nippon Chemiphar, Nihon Generic, Pfizer Japan, Mylan, and Yutoku Pharmaceutical. Revenue generated through product manufacturing fees.
3. Overseas Pharmaceutical Export: Export of FDA-approved ZTlido (lidocaine topical system) 1.8% to the United States through co-development and commercialization partner Scilex Pharmaceuticals for treatment of postherpetic neuralgia. First exported ethical pharmaceutical product for the company.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Oishi Koseido develops, manufactures, and sells adhesive transdermal patches (gel patches, plasters, and tapes) for both over-the-counter (OTC) self-medication and prescription (ethical) pharmaceutical use, drawing on 110+ years of formulation heritage. The company produces its own branded products for pain relief and provides GMP-compliant OEM contract manufacturing of adhesive transdermal patches to over 150 pharmaceutical company partners. It also co-developed and exports ZTlido, an FDA-approved lidocaine topical system, to the United States through a commercialization partner.

Product overview

Oishi Koseido is a pharmaceutical manufacturer specializing in adhesive transdermal patch technology with 110+ years of history since founding in 1907. The company operates two product divisions: Over-the-Counter (OTC) drugs and Prescription (ethical) drugs, plus a cosmetics line. OTC products include gel patches (冷感/温感パスマンシップS, パスマンシップID, ロキエフェクトLXパップ) and tapes/plasters (ビーエスバン series, フェルビナファインα, ロキエフェクトLXテープα series). Prescription products include gel patches (ハップスターID, フェルビナクパップ70mgユートク) and tapes (ケトプロフェンテープパテル series, ツロブテロールテープVTRS series). The flagship international product is ZTlido™ 1.8%, an FDA-approved lidocaine patch for postherpetic neuralgia launched in the US market in 2018. The company also provides OEM contract manufacturing services to 150+ pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Products and services

• ZTlido 1.8% (Lidocaine Topical System) FDA-approved transdermal lidocaine patch for postherpetic neuralgia (PHN) treatment; proprietary formulation delivers equivalent analgesic effect to competing lidocaine patches with significantly less active ingredient.
• Cooling YOU-Shippu S (冷感パスマンシップS) Cooling gel patch OTC analgesic containing salicyl glycol, l-menthol, and tocopherol acetate for acute inflammatory conditions; available in 30 or 50 sheets of 10cm×14cm.
• Warming YOU-Shippu S (温感パスマンシップS) Warming gel patch OTC analgesic containing capsicum extract for chronic inflammatory conditions; 30 sheets of 10cm×14cm.
• YOU-Shippu i 1.0% (パスマンシップID1.0%) OTC gel patch containing indomethacin (1.0g) and tocopherol acetate for muscle pain, joint pain, shoulder pain, lower back pain, tendosynovitis, elbow pain, bruises, and sprains.
• Loxi Effect LX Pap (ロキエフェクトLXパップ) OTC gel patch containing loxoprofen sodium hydrate (1.134g) for joint pain, shoulder pain, muscle pain, lower back pain, bruises, sprains, tendosynovitis, and tennis elbow.
• BS Ban Warming Patch (ビーエスバン温膏) OTC warming circular plaster patch (diameter 2.8cm) containing methyl salicylate, dl-camphor, l-menthol, tocopherol acetate, and nonanoic acid vanillylamide; 156 patches per pack.
• BS Ban Eα (ビーエスバンEα) OTC plaster containing methyl salicylate, l-menthol, dl-camphor, and tocopherol acetate; 140 patches of 6.5cm×4.2cm for muscle and joint pain.
• BS Ban Sα (ビーエスバンSα) OTC plaster containing methyl salicylate (10g), l-menthol (3g), and tocopherol acetate (2g); 120 patches of 7.2cm×4.6cm.
• Felbina Fine α (フェルビナファインα) OTC tape containing felbinac (3.5g) and l-menthol (3.0g); 80 patches of 7.0cm×5.5cm for shoulder pain, lower back pain, joint pain, muscle pain, bruises, sprains, tenosynovitis, and tennis elbow.
• BS Ban FR Tape Vα (ビーエスバンFRテープVα) OTC tape containing felbinac (5.00g), l-menthol (4.20g), tocopherol acetate (2.30g), and glycyrrhizinic acid (0.19g); available in 20, 50, or 16 large patches (10cm×14cm).
• BS Ban ZX Tape (ビーエスバンZXテープ) OTC tape containing diclofenac sodium (2g) and l-menthol (3.5g); available in 7, 14, 21 patches of 7cm×10cm, or 7 large patches of 10cm×14cm.
• BS Ban SG Tape (ビーエスバンSGテープ) OTC tape containing salicyl glycol (8.0g), l-menthol (5.0g), and tocopherol acetate (0.5g); 32 patches of 7cm×10cm.
• Loxi Effect LX Tape α (ロキエフェクトLXテープα) OTC tape containing loxoprofen sodium hydrate (8.1g), l-menthol (3.5g), and tocopherol acetate (2.3g); available in 7, 14, or 21 patches of 7cm×10cm.
• Warming Loxi Effect LX Tape α (温感ロキエフェクトLXテープα) OTC warming tape containing loxoprofen sodium hydrate (8.1g) and nonanoic acid vanillylamide (0.03g) for warming pain relief.
• HAPSTAR ID 70mg (ハップスターID70mg) Prescription gel patch containing indomethacin (70mg); indicated for osteoarthritis, frozen shoulder, tendonitis/tenosynovitis, peritendinitis, humeral epicondylitis, muscle pain, and post-traumatic swelling/pain. Available in 250, 500, or 700 sheets.
• Felbinac PAP 70mg YUTOKU (フェルビナクパップ70mg「ユートク」) Prescription gel patch containing felbinac (70mg); available in 140, 350, or 700 sheets of 10cm×14cm.
• Ketoprofen Tape 20mg PATELL (ケトプロフェンテープ20mg「パテル」) Prescription tape containing ketoprofen (20mg); indicated for lower back pain, osteoarthritis, frozen shoulder, tendonitis/tenosynovitis, humeral epicondylitis, and rheumatoid arthritis pain. Available in 70 or 700 sheets of 7cm×10cm.
• TULOBUTEROL Tape 0.5mg VTRS (ツロブテロールテープ0.5mg「VTRS」) Prescription bronchodilator tape containing tulobuterol (0.5mg); indicated for bronchial asthma, acute bronchitis, chronic bronchitis, and lung emphysema. 70 sheets of 16.0mm×16.0mm.
• TULOBUTEROL Tape 1mg VTRS (ツロブテロールテープ1mg「VTRS」) Prescription bronchodilator tape containing tulobuterol (1.0mg); 70 sheets of 22.5mm×22.5mm.
• TULOBUTEROL Tape 2mg VTRS (ツロブテロールテープ2mg「VTRS」) Prescription bronchodilator tape containing tulobuterol (2.0mg); 70 sheets of 32.0mm×32.0mm.
• Satta Men's Cosmetics (サッタ) All-in-one men's skincare cosmetic developed in partnership with Saga University. Awarded the 'Globally Soaring Saga Monozukuri Person Award' for innovative product development.
• OEM Contract Manufacturing Services OEM manufacturing services for gel patches, plasters, and tapes with GMP-compliant facilities. Serves 150+ pharmaceutical company partners including Kyorin Rimedio, Takata Pharmaceutical, Teikoku Seiyaku, Nichi-Iko, Nippon Chemiphar, Pfizer Japan, and Mylan. Manufacturing capabilities include FDA and international GMP standards.

Quantifiable outcome

• ZTlido delivers equivalent analgesic effect to 700mg lidocaine patches using only 36mg of lidocaine per patch (~95% less active ingredient)
• +3 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core, major, strategic and minor.

• Scilex Pharmaceuticals (Subsidiary of Sorrento Therapeutics)coreStrategic or Co-development Partner · 28 February 2018Scilex Pharmaceuticals is the US commercialization partner for ZTlido (lidocaine topical system) 1.8%. Oishi Koseido co-developed ZTlido with Scilex and obtained FDA approval together through bioequivalence studies and safety trials. Scilex handles all sales and distribution in the United States, launching the product in October 2018. The partnership represents the company's first overseas ethical pharmaceutical export and is a cornerstone of its global expansion strategy.
• Kyorin Rimedio Co., Ltd.coreChannel Partner/ Reseller/ DistributorOne of the major OEM customers for adhesive transdermal patch manufacturing. Kyorin Rimedio distributes pharmaceutical products including adhesive patches through the Japanese pharmaceutical distribution network to medical institutions and pharmacies.
• Takata Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ DistributorMajor OEM customer for contract manufacturing of adhesive transdermal patches. Takata Pharmaceutical is a Japanese generic pharmaceutical company serving hospitals and clinics across Japan.
• Teikoku Seiyaku Co., Ltd.coreChannel Partner/ Reseller/ DistributorKey OEM manufacturing partner for adhesive transdermal patches. Teikoku Seiyaku is known for its domestically produced pharmaceutical products distributed throughout Japan.
• Nichi-Iko Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ DistributorOEM customer for contract manufacturing of gel patches, plasters, and tapes. Nichi-Iko is one of Japan's leading generic pharmaceutical companies with nationwide distribution reach.
• Nippon Chemiphar Co., Ltd.majorChannel Partner/ Reseller/ DistributorMajor OEM customer for adhesive transdermal patch manufacturing. Nippon Chemiphar distributes specialty and generic pharmaceutical products through medical institutions.
• Nihon Generic Co., Ltd.majorChannel Partner/ Reseller/ DistributorOEM customer for generic transdermal patch manufacturing. Nihon Generic focuses on the supply of high-quality generic pharmaceutical products.
• Pfizer Japan Inc.majorChannel Partner/ Reseller/ DistributorMajor multinational pharmaceutical company sourcing adhesive transdermal patch manufacturing from Oishi Koseido for its Japanese market product portfolio.
• Mylan Seiyaku Ltd. (now part of Viatris)majorChannel Partner/ Reseller/ DistributorGlobal generic pharmaceutical company (now part of Viatris) sourcing transdermal patch manufacturing from Oishi Koseido for Japanese market distribution.
• Yutoku Pharmaceutical Industry Co., Ltd.coreChannel Partner/ Reseller/ DistributorMajor OEM customer for gel patch manufacturing. Yutoku Pharmaceutical Industry supplies products throughout the Japanese pharmaceutical distribution network.
• Saga University (Professor Tokudome)strategicStrategic or Co-development PartnerCollaborative research development with Saga University, including joint development work with Professor Tokudome. Researchers from Oishi Koseido, along with the Saga University professor, reported progress to Saga Prefecture Governor Yamaguchi in July 2022.
• SAGA HIMAT (九州国際重粒子線がん治療センター)minorOthersSAGA HIMAT (Saga Heavy Ion Medical Accelerator in Tosu) — Oishi Koseido made a charitable donation to this cancer treatment center in November 2012 as part of its CSR activities.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Sun Pharmaceutical Industries: Large global specialty/generics manufacturer with transdermal drug delivery capability (e.g., Taro's US transdermal operations). Comparable as a broad incumbent with branded-generic transdermal exposure.
• Teva Pharmaceutical Industries: Global generic and specialty pharmaceutical company with a meaningful transdermal patch portfolio (e.g., generic lidocaine patches, hormone patches) and broader scale across prescription, OTC, and CMO services. Overlaps with Oishi's OEM relationships and US ZTlido competition.
• Viatris (formerly Mylan): Global generics giant with transdermal and topical prescription products, including a US lidocaine patch franchise. Notable overlap as both an Oishi Koseido OEM customer in Japan and a US transdermal patch competitor.
• Church & Dwight: US consumer products company with an OTC patch franchise (including topical analgesic products), operating broadly across personal care with a comparable OTC distribution model to Oishi's Japanese pharmacy/drugstore channel.

Direct peers

• Teikoku Seiyaku: Japanese pharmaceutical manufacturer specializing in topical pain patches and prescription transdermal products (Mohrus, Salonsip). Directly comparable as a domestic Japanese competitor in adhesive transdermal patches, including OEM operations.
• Hisamitsu Pharmaceutical: Japan's leading manufacturer of OTC and prescription transdermal pain patches (Salonpas, Mohrus), holding dominant domestic market share. Directly comparable as a Japanese transdermal patch specialist competing in both OTC and ethical pharmaceutical segments.
• Sato Pharmaceutical: Mid-sized Japanese OTC pharmaceutical manufacturer with overlapping pain relief, dermatology, and self-medication product lines sold through pharmacies and drugstores across Japan. Comparable size and portfolio scope.
• Kobayashi Pharmaceutical: Japan-focused OTC pharmaceutical and consumer health company with a range of pain relief patches and topical products (including the Air Salonpas series). Comparable as a Japanese OTC consumer health manufacturer serving pharmacy and drugstore channels.
• Endo International (Par Pharmaceutical): Markets the generic equivalent of the original Lidoderm lidocaine patch in the United States — a direct competitor to Oishi Koseido's ZTlido in the postherpetic neuralgia segment.

Emerging players

• Ikeda Mohando: Japanese OTC pharmaceutical company best known for the Yoko Yoko adhesive patch brand — a direct competitor in Japanese OTC pain relief patches, smaller in scale than Hisamitsu but operating in Oishi's core category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oishi Koseido